| 目录号 |
产品名 |
中文名称 |
产品描述 |
参考文献 |
|
S4430
|
HCQ (Hydroxychloroquine) Sulfate
|
|
|
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
|
|
S2853
|
PR-171 (Carfilzomib)
|
|
|
Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study
|
|
S7975
|
Favipiravir (T-705)
|
|
|
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
|
|
S1835
|
Azithromycin
|
阿奇霉素,阿齐红霉
|
Azithromycin是一种抑制蛋白合成的抗生素，用于细菌感染的治疗。
|
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
|
|
S1620
|
Darunavir Ethanolate
|
地瑞那韦乙醇盐
|
Darunavir Ethanolate (TMC-114, UIC 94017)是一种人类免疫缺陷病毒(HIV)蛋白酶抑制剂。
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S4646
|
Ciclesonide
|
环索奈德
|
Ciclesonide (Alvesco, Omnaris, RPR251526, Zetonna)是一种糖皮质激素，用于治疗阻塞性气道疾病。
|
Therapeutic potential of ciclesonide inhalation for COVID-19 pneumonia: Report of three cases
|
|
S3035
|
Daunorubicin Hydrochloride (Daunomycin)
|
|
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S4157
|
Chloroquine diphosphate
|
二磷酸氯喹
|
Chloroquine diphosphate是一种4-氨基喹啉的抗疟疾和抗风湿药，也是一种ATM激活剂。Chloroquine 也是一种toll-like receptors (TLRs)的抑制剂。
|
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
|
|
S2823
|
Tideglusib
|
|
Tideglusib是一种不可逆的，非ATP竞争性的GSK-3β抑制剂，无细胞试验中IC50为60 nM，不能抑制位于活性位点的同源于 Cys-199的 Cys激酶。Phase 2。
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S2874
|
Camostat Mesilate
|
甲磺酸卡莫司他
|
Camostat (FOY-305, FOY-S980)是胰蛋白酶样的蛋白酶抑制剂，抑制上皮细胞钠离子通道(ENaC)功能，IC50为50 nM, 对Trypsin, Prostasin 和 Matriptase作用效果稍弱。
|
The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19)
|
|
S8932
|
GS-5734 (Remdesivir)
|
|
|
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
|
|
S5911
|
Bictegravir
|
比克替拉韦
|
Bictegravir (GS-9883)是一种新型的、有效的HIV-1 integrase抑制剂。
|
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
|
|
S1759
|
Pitavastatin (NK-104) Calcium
|
|
|
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
|
|
S1680
|
Tetraethylthiuram disulfide (Disulfiram)
|
|
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S1386
|
Nafamostat mesilate (FUT-175)
|
甲磺酸萘莫司他
|
Nafamostat mesilate (FUT-175)是合成的丝氨酸蛋白酶抑制剂，在血液透析中被用作是一种抗凝血剂。Nafamostat Mesylate可抑制SARS-CoV-2的激活，并用于COVID-19的治疗选择的研究中。Nafamostat Mesylate 可减弱炎症和凋亡。
|
Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission
|
|
S1706
|
Lamivudine (3TC, BCH-189)
|
|
|
COVID-19 Registered Trials – and analysis
|
|
S8279
|
(±)-Shikonin
|
紫草素
|
(±)-Shikonin是一种 Pyruvate kinase M2 (PKM2) 有效的、特异的抑制剂。它是紫草的主要成分，紫草是一种中草药，具有多种生物活性。在细胞荧光淬灭试验中，Shikonin也是TMEM16A氯离子通道的抑制剂。Shikonin 通过抑制 tumor necrosis factor-α (TNF-α) 发挥抗炎作用，并可通过抑制 proteasome 来阻止 nuclear factor-κB (NF-κB) 信号途径的激活。
|
|
|
S1380
|
Lopinavir (ABT-378)
|
洛匹那韦
|
Lopinavir (ABT-378) 是一种有效的HIV protease抑制剂，无细胞试验中Ki为1.3 pM。
|
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicin
|
|
S2485
|
Mitoxantrone Dihydrochloride (NSC 301739)
|
|
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S4282
|
Nelfinavir Mesylate
|
甲磺酸奈非那韦
|
Nelfinavir Mesylate是强效的HIV protease抑制剂，Ki为2 nM。
|
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
|
|
S1185
|
Ritonavir
|
利托那韦
|
Ritonavir是Cytochrome P450 3A和HIV蛋白酶抑制剂，用于治疗HIV感染和AIDS。抑制Cytochrome P450 2D6, P-Glycoprotein，诱导Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6和UDP Glucuronosyltransferases。Ritonavir 可诱导凋亡。
|
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicin
|
|
S1351
|
Ivermectin
|
伊维菌素, 依维菌素
|
Ivermectin是一种chloride channel激活剂，用作广谱抗寄生虫药。Ivermectin (MK-933, IVM) 是 P2X4 和 α7 nicotinic acetylcholine receptors (nAChRs) 的特异性正变构效应物。Ivermectin (MK-933) 是一种特异性的 Impα/β1 介导的核导入抑制剂，对 HIV-1 和登革热dengue virus均具有有效的抗病毒活性。Ivermectin 可通过AKT/mTOR信号通路来诱导自噬，并诱导线粒体自噬。
|
Parasite Drug Shows Early Promise
Against COVID-19 in Vitro
|
|
S1401
|
Tenofovir
|
替诺福韦, 泰诺福韦
|
Tenofovir (GS-1278) 对reverse transcriptase（逆转录酶）和B型肝炎病毒感染具有抑制作用。
|
COVID-19 Registered Trials – and analysis
|
|
S5250
|
Darunavir
|
达芦那韦,地瑞那韦
|
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S7579
|
Ledipasvir (GS5885)
|
雷迪帕韦
|
Ledipasvir (GS5885) 是一种HCV NS5A polymerase抑制剂，用于治疗丙型肝炎病毒感染。
|
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repur
|
|
S1538
|
Telaprevir
|
特拉匹韦
|
Telaprevir (VX-950, LY-570310, MP-424)是一种丙型肝炎病毒(HCV)NS3-4A丝氨酸蛋白酶抑制剂，IC50为0.354 μM。
|
α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
|
|
S1183
|
Danoprevir
|
丹诺瑞韦
|
Danoprevir (ITMN-191, RG7227) 是一种肽类抑制剂，作用于丙型肝炎病毒(HCV)的NS3/4A蛋白酶，IC50为0.2-3.5 nM，抑制HCV 1A/1B/4/5/6基因型比抑制2B/3A基因型效果高10倍左右。Phase 2。
|
First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients
|
|
S2169
|
Rosuvastatin calcium
|
|
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S1289
|
Carmofur
|
卡莫氟
|
Carmofur (HCFU) 是嘧啶类似物，是一种作抗肿瘤药。
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S7947
|
PX-12
|
|
PX-12 (DB05448, 1-methyl propyl 2-imidazolyl disulfide)是一种有效的 thioredoxin-1 (Trx-1) 抑制剂，作用于 Trx-1 上 Cys73 的不可逆硫代烷基化。Phase 2。
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S3079
|
Atovaquone
|
阿托喹酮
|
Atovaquone (Atavaquone)用于治疗或预防肺孢子菌肺炎，弓形虫病, 疟疾和巴贝西虫。
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S2926
|
TDZD-8
|
|
TDZD-8 (NP 01139) 是一种非ATP竞争性GSK-3β抑制剂，IC50为2 μM；对CDK1， casein kinase II， PKA和PKC具有最低限度的抑制效果。
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S1691
|
Praziquantel
|
吡喹酮
|
Praziquantel是一种驱虫药，有效作用于扁形虫。
|
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
|
|
S3733
|
Boceprevir
|
博赛泼维,波普瑞韦
|
Boceprevir (EBP 520, SCH 503034)是一种口服的、直接作用于hepatitis C virus (HCV) protease的抑制剂，对NS3蛋白酶的Ki值为14 nM。在治疗慢性肝炎C(genotype 1)中，常与其他抗病毒共同给药。
|
α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
|
|
S3724
|
Velpatasvir
|
维帕他韦
|
Velpatasvir (GS-5816,VEL) 是二代NS5A抑制剂，抑制丙型肝炎病毒（HCV）的复制。
|
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repur
|
|
S2071
|
Prulifloxacin (NM441)
|
普鲁利沙星,普卢利沙星
|
Prulifloxacin (NM441, AF 3013)是ulifloxacin的前体药物，是一种广谱喹诺酮类抗菌药。
|
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
|
|
S9567
|
Indinavir Sulfate
|
硫酸茚地那韦
|
Indinavir sulfate (Crixivan, L-735524, MK-639)是一种有效的、特异的HIV-1 protease抑制剂，广泛用于艾滋病的治疗。
|
Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking
|
|
S2079
|
Moexipril HCl
|
莫西普利
|
Moexipril HCl (RS-10085)是一种口服有效的非巯基血管紧张素转化酶（ACE）抑制剂，IC50为0.041 µM，用于治疗高血压和充血性心脏衰竭。
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S3037
|
Bepotastine Besilate
|
苯磺贝他斯汀
|
Bepotastine Besilate (TAU 284)是一种非镇静作用的，选择性的组胺1 (H1)受体拮抗剂，pIC50为5.7。
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S5940
|
Bepotastine
|
贝他斯汀
|
Bepotastine是一种非镇静的、选择性histamine 1 (H1) receptor拮抗剂。
|
Many drugs already approved by FDA may have promise against COVID-19
|
|
S6676
|
Ebselen
|
依布硒
|
Ebselen (DR 3305, SPI-1005, PZ-51, CCG-39161)是HIV-1复制的小分子衣壳抑制剂，在TR-FRET分析中的IC50为46.1 nM。
|
Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors
|
|
S8969
|
Molnupiravir (EIDD-2801)
|
|
Molnupiravir (EIDD-2801, MK-4482) 是一种口服生物活性的核糖核苷类似物β-d-N4-hydroxycytidine (NHC; EIDD-1931)的前药，具有广谱的抗病毒活性 antiviral activity 对抗 SARS-CoV-2、MERS-CoV、SARS-CoV 和 COVID-19的病原体。
|
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
|
